Valion Bio, Inc. (VBIO): Nasdaq/NYSE listing notice — Tivic Health regains Nasdaq compliance after reverse split; delisting averted

Valion Bio, Inc.

Nasdaq notified Tivic on Sept 15, 2023 that bid price deficiency is cured.
Company effected 1-for-100 reverse stock split on Aug 21, 2023 to cure deficiency.
Nasdaq cancelled the hearing and reversed its delisting determination.
Common stock continues trading on Nasdaq Capital Market under TIVC.
No financial impact disclosed beyond compliance status.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Valion Bio, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

September 15, 2023, Nasdaq notified the Company that the Company’s bid price deficiency has been cured and that the Company is in compliance with all applicable listing standards. As a result, Nasdaq has cancelled the Hearing, reversed its delisting determination and confirmed that the Company’s common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “TIVC.”

View on SEC.gov

Browse all listing & compliance notices →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-238127

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.